Panagora Asset Management’s Outlook Therapeutics OTLK Stock Holding History

Panagora Asset Management’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-66	Closed	-$3K	–	2588
2019 Q2	$3K	Sell	66 -198	-75%	-$9.23K	﹤0.01%	2509
2019 Q1	$39K	Sell	264 -117	-31%	-$16.5K	﹤0.01%	2103
2018 Q4	$30K	Buy	381 +148	+64%	+$18.2K	﹤0.01%	2114
2018 Q3	$37K	Sell	233 -143	-38%	-$20.1K	﹤0.01%	2089
2018 Q2	$51K	Buy	376 +19	+5%	+$2.8K	﹤0.01%	2034
2018 Q1	$51K	Sell	357 -168	-32%	-$30K	﹤0.01%	2023
2017 Q4	$109K	Buy	525 +148	+39%	+$30.7K	﹤0.01%	1850
2017 Q3	$83K	Sell	377 -28	-7%	-$5.09K	﹤0.01%	1933
2017 Q2	$65K	Buy	+405	New	+$114K	﹤0.01%	2005

Other funds holding OTLK

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RIA

Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

Panagora Asset Management's OTLK Position: Q3 2019 in Review

Panagora Asset Management sold out of Outlook Therapeutics (OTLK) in Q3 2019, closing a stake of 66 shares — an estimated $3K sold.

Panagora Asset Management first reported a position in OTLK in Q2 2017 and held it in 9 quarters. The position peaked at $109K in Q4 2017. 15 funds tracked by Wall St. Rank hold OTLK as of Q3 2019.

Panagora Asset Management reported no remaining Outlook Therapeutics position as of Q3 2019 after selling out during the quarter.
Panagora Asset Management sold 66 Outlook Therapeutics shares in Q3 2019, an estimated $3K.
Panagora Asset Management first reported a position in Outlook Therapeutics in Q2 2017 and held it in 9 quarters.
Panagora Asset Management's Outlook Therapeutics position peaked at $109K in Q4 2017.
15 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2019.

Based on Panagora Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.